Halozyme Therapeutics, Inc. - Common Stock — 현금 흐름 (NASDAQ:HALO)

Financials

영업활동으로 인한 현금 55.45 M299.44 M240.11 M388.57 M479.06 M651.56 M 677.41 M 투자 활동으로 인한 현금 78.35 M-406.29 M-487 M-96.91 M-262.72 M-545.81 M -458.27 M 재무활동으로 인한 현금 -106.28 M77.86 M362.37 M-407.99 M-218.86 M-85.17 M -83.47 M 잉여 현금 흐름 55.45 M299.44 M240.11 M388.57 M479.06 M644.59 M 667.65 M

Halozyme Therapeutics, Inc. - Common Stock

Halozyme Therapeutics, Inc. is an American biotechnology company. It develops oncology therapies designed to target the tumor microenvironment. The company was founded in 1998 and went public in 2004. Halozyme is headquartered in San Diego, California.

HALO

Financials

Halozyme Therapeutics, Inc. - Common Stock

뉴스

Is MYGN Stock a Buy at 0.4x Sales? What Investors Should Weigh

MYGN Cancer Care Strategy: What's Driving 2026 Growth Plans

Implied Volatility Surging for Halozyme Therapeutics Stock Options

Halozyme Therapeutics: Royalty King (NASDAQ:HALO)

Company News for May 13, 2026

Halozyme's Q1 Earnings & Revenues Beat Estimates, Stock Up

Halozyme Therapeutics, Inc. 2026 Q1 - Results - Earnings Call Presentation (NASDAQ:HALO) 2026-05-11

Halozyme Therapeutics (HALO) Reports Q1 Earnings: What Key Metrics Have to Say

Halozyme Therapeutics (HALO) Surpasses Q1 Earnings and Revenue Estimates

ANI Pharmaceuticals (ANIP) Tops Q1 Earnings and Revenue Estimates

ImmunityBio (IBRX) Reports Q1 Loss, Tops Revenue Estimates

Halozyme Therapeutics (HALO) Q1 Earnings on the Horizon: Analysts' Insights on Key Performance Measures